The second one is a Phase I/II trial that will evaluate the effects of the third generation EGFR-TKI, osimertinib in combination with dasatinib in EGFR mutant NSCLC patients who developed resistance to the first-generation EGFR-TKIs, erlotinib and gefitinib, aiming to assess serum biomarkers to monitor clinical outputs upon c-Src inhibitor treatments. This evidence concerns the gene EGFR and non-small cell lung carcinoma.